Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zaleplon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 1.00 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 1/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 1/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 1/20 | 1.00 |
| ▸ | AOX1 | Q06278 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zaleplon SCHEMBL29118 | 1.00 | KDM4E (1.00) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL5605771 | 1.00 | KDM4E (1.00) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL4727312 | 0.99 | KDM4E (0.98) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL4726630 | 0.99 | KDM4E (0.98) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL27637735 | 0.98 | KDM4E (0.96) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL4726658 | 0.96 | KDM4E (0.93) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL4726073 | 0.96 | KDM4E (0.93) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| SCHEMBL3166147 | 0.93 | KDM4E (0.87) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| SCHEMBL3164210 | 0.92 | KDM4E (0.86) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| SCHEMBL3168939 | 0.91 | KDM4E (0.84) | KDM4EMAPK1GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171439-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-05-29 | — | — | US | disclosed |
| CN-115636833-B | Substituted imidazo [4,5-c ] cinnolin-2-one compounds as selective modulators of ATM kinases and uses thereof | 苏州赞荣医药科技有限公司 | 2024-11-29 | — | — | CN | disclosed |
| EP-4308569-A1 | SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | Suzhou Zanrong Pharma Limited (CN) | 2024-01-24 | — | — | EP | disclosed |
| US-20230391778-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-12-07 | — | — | US | disclosed |
| CN-115636833-A | Substituted imidazo [4,5-c ] cinnolin-2-one compounds as selective modulators of ATM kinases and uses thereof | 苏州赞荣医药科技有限公司 | 2023-01-24 | — | — | CN | disclosed |
| WO-2022193166-A1 | SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022194138-A1 | SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2022-09-22 | — | — | WO | disclosed |
| US-20220259206-A1 | Preparation Method of Zaleplon | ANHUI UNIVERSITY OF TECHNOLOGY (CN) | 2022-08-18 | — | — | US | disclosed |
| US-11389453-B2 | Compositions and methods for treating chemosensory dysfunction | CYRANO THERAPEUTICS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3324975-B1 | COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF | HSU JOHN (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-112724150-B | Preparation method of zaleplon | 新乡医学院 | 2022-03-04 | — | — | CN | disclosed |
| US-20220033395-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259206-A1 | Preparation Method of Zaleplon | COMT, PNMT, HNMT | GABRA1 934/4885GABRG2 1992/4885KDM4E 421/4885 |
| US-20230391778-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | GABRA1 88/4885GABRG2 393/4885KDM4E 4502/4885 |
| US-20220033395-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | GABRA1 88/4885GABRG2 393/4885KDM4E 4502/4885 |
| US-20250171439-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | GABRA1 88/4885GABRG2 393/4885KDM4E 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.